GH Research (GHRS)
(Delayed Data from NSDQ)
$11.30 USD
+0.32 (2.91%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $11.09 -0.21 (-1.86%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GHRS 11.30 +0.32(2.91%)
Will GHRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GHRS
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
GHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
New Strong Buy Stocks for October 25th
Other News for GHRS
GH Research PLC Shareholders Approve Board Resolutions
GH Research Engages Investors at Upcoming Conferences
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why